Key Highlights

  • Regeneron shares rose 12.12% on October 30, 2026.
  • Third-quarter Revenue rose 36% to $5.1 billion.
  • Adjusted Earnings of $20.07 per share beat the $16.42 expected.
  • Healthcare stocks held up better than technology on the day.

Regeneron Pharmaceuticals (NASDAQ:REGN) posted one of the largest gains among big-cap stocks on Friday, rising 12.12% after reporting third-quarter results that showed revenue up 36% to $5.1 billion, according to market reports. For a company of Regeneron's size a move of this magnitude is unusual, and it came on a day when the broader market was under heavy pressure.

A Large Earnings Beat

Adjusted Earnings Per Share came in at $20.07, compared with the $16.42 that had been expected, a gap of more than $3.60. Revenue growth on that scale is striking for a mature biotech and suggests the company's main growth drivers delivered a strong quarter. Investors had spent a long stretch worrying about competition and pricing pressure in ophthalmology, where Eylea faces newer treatments and biosimilar threats, so results showing the overall Business expanding rapidly help ease those concerns for now.

What Regeneron Does

Regeneron develops and commercializes antibody medicines. Its portfolio has long been anchored by Eylea for retinal diseases and by Dupixent, the immunology drug it develops with Sanofi. Because earnings include both its own product sales and its share of collaboration profits, quarterly results can swing on a small number of very large franchises.

A Defensive Rotation Helped

The S&P 500 fell 140.32 points, or 1.8%, to 7,580.07 and the Nasdaq Composite dropped 747.73 points, or 2.9%, to 25,437.00, as Intel (NASDAQ:INTC)'s weak outlook triggered a chip rout and Amazon (NASDAQ:AMZN)'s results revived worries about AI spending. Healthcare and pharma stocks were among the groups that held up better, alongside consumer staples and energy, and AstraZeneca (NYSE:AZN) also gained after its own results. Regeneron's surge went well beyond what a rotation alone would explain, pointing to the earnings report as the primary driver.

Durability of Growth

Investors will focus on the durability of growth, the trajectory of key franchises and pipeline progress. Management commentary on competition in retinal disease and the expansion of its immunology business will help show whether the third quarter represents a new baseline. Drug pricing debates and the November 3 midterm elections are also factors large pharma investors monitor.